Biogen Inc.

BIIBleader

Biogen is a pioneer in neuroscience therapeutics, leading in multiple sclerosis treatments and advancing Alzheimer's disease therapy with Leqembi alongside a profitable biosimilars business.

⇄ Compare

Products & Revenue

Product Revenue Share

Revenue Breakdown ($9.8B)

Static data (loading live financials…)

Multiple Sclerosis (38%)

Biosimilars (28%)

Rare Disease (18%)

Alzheimer's & Other (16%)

Segment Breakdown & Key Customers

Product Details

Leqembi (lecanemab)15%

Anti-amyloid antibody for early Alzheimer's disease (co-developed with Eisai)

Multiple Sclerosis Portfolio40%

Tecfidera, Vumerity, Tysabri, and Avonex for MS

Rare Disease (SMA)15%

Spinraza (nusinersen) for spinal muscular atrophy

Biosimilars30%

Biosimilar versions of TNF inhibitors and oncology drugs

Supply Chain Relationships

Competitors

Regeneron Pharmaceuticals

Neuroscience pipeline

Impact: Low — limited direct overlap

Eli Lilly and Company

Alzheimer's disease treatments

Impact: High — Lilly's donanemab vs Leqembi

Viatris Inc.

Biosimilar market

Impact: Medium — both in biosimilars

Macro & Market Context

제약 / 바이오Sector News

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Upcoming Catalysts

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Latest News

Loading news...

AI Analysis

Click "Get AI Analysis" for an AI-powered supply chain analysis of Biogen Inc..

Company Info

Headquarters

Cambridge, Massachusetts, USA

Founded

1978

Employees

7,500+

Website

biogen.com

Sector Overview — 제약 / 바이오

Sector News